- Home
- EHTH vs KOD Comparison
EHTH vs KOD Comparison
Compare EHTH & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHTH
- KOD
- Stock Information
- Founded
- EHTH 1997
- KOD 2009
- Country
- EHTH United States
- KOD United States
- Employees
- EHTH N/A
- KOD N/A
- Industry
- EHTH Specialty Insurers
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EHTH Finance
- KOD Health Care
- Exchange
- EHTH Nasdaq
- KOD Nasdaq
- Market Cap
- EHTH 247.3M
- KOD 186.3M
- IPO Year
- EHTH 2006
- KOD 2018
- Fundamental
- Price
- EHTH $8.32
- KOD $8.72
- Analyst Decision
- EHTH Hold
- KOD Hold
- Analyst Count
- EHTH 5
- KOD 5
- Target Price
- EHTH $7.70
- KOD $6.80
- AVG Volume (30 Days)
- EHTH 344.0K
- KOD 484.9K
- Earning Date
- EHTH 11-06-2024
- KOD 11-14-2024
- Dividend Yield
- EHTH N/A
- KOD N/A
- EPS Growth
- EHTH N/A
- KOD N/A
- EPS
- EHTH N/A
- KOD N/A
- Revenue
- EHTH $464,891,000.00
- KOD N/A
- Revenue This Year
- EHTH $9.78
- KOD N/A
- Revenue Next Year
- EHTH $5.99
- KOD N/A
- P/E Ratio
- EHTH N/A
- KOD N/A
- Revenue Growth
- EHTH 15.78
- KOD N/A
- 52 Week Low
- EHTH $3.58
- KOD $2.19
- 52 Week High
- EHTH $9.45
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- EHTH 81.77
- KOD 64.72
- Support Level
- EHTH $5.42
- KOD $8.03
- Resistance Level
- EHTH $8.98
- KOD $9.55
- Average True Range (ATR)
- EHTH 0.48
- KOD 0.89
- MACD
- EHTH 0.30
- KOD -0.08
- Stochastic Oscillator
- EHTH 82.16
- KOD 36.51
About EHTH eHealth Inc.
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare and Employer and Individual. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.